About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
University of Miami Sylvester Comprehensive Cancer Center
COVID-19
Videos
Lung
Lymphoma
Leukemia
2nd Biennial Miami Leukemia Symposium
AML Biology and Treatment
MDS Biology and Treatment
ALL Biology and Treatment
CLL Therapy in 2019
CML and MPNs: Final Frontiers and New Breakthroughs
Myeloid Biology and Novel Therapies
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
M
Frontline Therapies in MDS: Leveling Lower-risk MDS
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Mikkael Sekeres
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Mikkael Sekeres
0 views
May 14, 2020
Comments
0
Login to view comments.
Click here to Login
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Featured Video
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
MDS Biology and Treatment
25:42
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on MDS Mutational Landscape: What Are the Most Common MD…
Feat.
R. Bejar
20:06
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…
Feat.
T. Graubert
22:02
University of Miami's 2nd Biennial Miami Leukemia Symposium
TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…
Feat.
A. Verma
12:19
University of Miami's 2nd Biennial Miami Leukemia Symposium
How to Calculate Risk in MDS Patients?
Feat.
M. Sekeres
14:36
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Leveling Lower-risk MDS
Feat.
M. Sekeres
05:28
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Hampering Higher-risk MDS
Feat.
M. Sekeres
10:48
University of Miami's 2nd Biennial Miami Leukemia Symposium
Hypomethylating Agents as SoC in MDS/AML: Clearance of TP53 Mutation…
Feat.
D. Sallman
08:13
University of Miami's 2nd Biennial Miami Leukemia Symposium
Discussion on the Data of Frontline Combination Therapy with APR-246…
Feat.
D. Sallman
05:21
University of Miami's 2nd Biennial Miami Leukemia Symposium
Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Chec…
Feat.
D. Sallman
27:33
University of Miami's 2nd Biennial Miami Leukemia Symposium
Overcoming Adaptive Therapy Resistance in AML: IRAK Signalling (via …
Feat.
D. Starczynowski
